Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
Research Watch

Long Noncoding RNAs Mediate Androgen Receptor Activity

DOI: 10.1158/2159-8290.CD-RW2013-184 Published October 2013
  • Article
  • Info & Metrics
Loading
  • Major finding: PRNCR1 and PCGEM1 bind the androgen receptor (AR) and promote AR target gene activation.

  • Concept: These lncRNAs promote ligand-independent AR activity and castration-resistant prostate cancer growth.

  • Impact: Overexpression of PRNCR1 and PCGEM1 may drive castration resistance in prostate cancer.

Figure1

Long noncoding RNAs (lncRNA) expression is sometimes deregulated in human cancers, but the functional consequences are often unclear. PRNCR1 is a lncRNA that is located in a prostate cancer susceptibility locus, and PCGEM is a prostate-specific lncRNA that is overexpressed in high-risk prostate cancer patients. Yang and colleagues performed native RNA immunoprecipitation in paired benign prostatic hyperplasias and prostate cancers and observed that PRNCR1 and PCGEM1 specifically interacted with the androgen receptor (AR) in prostate cancer samples. Knockdown of PRNCR1 abolished the interactions between both lncRNAs and AR, whereas PCGEM knockdown had no effect on the binding of PRNCR1 to AR, indicating that PRNCR1 is required for PCGEM recruitment. Depletion of either PRNCR1 or PCGEM1 significantly reduced canonical AR target gene expression, and the vast majority of the lncRNA binding sites colocalized with AR-bound enhancer regions, consistent with a direct role of PRNCR1 and PCGEM1 in AR-mediated transcriptional activity. PRNCR1 and PCGEM1 were also capable of binding the ligand-independent, truncated form of AR found in castration-resistant prostate cancer (CRPC) and were highly expressed in CRPC cell lines. PRNCR1 and PCGEM1 were both required for the constitutive transactivation activity of truncated AR in CRPC cells, and knockdown of either PRNCR1 or PCGEM1 significantly inhibited the proliferation of a CRPC cell line both in vitro and in vivo. Mechanistically, PRNCR1 and PCGEM1 mediated the formation of chromatin loops between AR-bound enhancers and AR target gene promoters through the interaction of PCGEM with pygopus 2, a PHD domain-containing protein that binds H3K4me3 and is required for AR target gene activation. Together, these findings point to a role for PRNCR1 and PCGEM1 in regulation of the AR transcriptional program and suggest that their overexpression may contribute to prostate cancer progression and the development of CRPC.

Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, et al. lncRNA-dependent mechanisms of androgen receptor-regulated gene activation programs. Nature 2013 Aug 14 [Epub ahead of print].

  • ©2013 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 3 (10)
October 2013
Volume 3, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Long Noncoding RNAs Mediate Androgen Receptor Activity
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Long Noncoding RNAs Mediate Androgen Receptor Activity
Cancer Discov October 1 2013 (3) (10) OF27; DOI: 10.1158/2159-8290.CD-RW2013-184

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Long Noncoding RNAs Mediate Androgen Receptor Activity
Cancer Discov October 1 2013 (3) (10) OF27; DOI: 10.1158/2159-8290.CD-RW2013-184
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Mutations in Receptor Tyrosine Kinases Drive Histiocytic Disorders
  • Pembrolizumab Monotherapy Is Active in Metastatic Prostate Cancer
  • MYC Superenhancer–Nuclear Pore Binding Increases MYC-Transcript Export
Show more Research Watch

Prostate Cancer

  • Mutations in FOXA1 Cluster into Distinct Structural and Phenotypic Classes
  • Mitochondrial Fission Promotes Prostate Cancer Stem-Cell Self-Renewal
  • Delta-like Protein 3 Is a Target in Neuroendocrine Prostate Cancer
Show more Prostate Cancer
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement